Published in Cancer Cell on June 02, 2009
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 6.53
Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell (2014) 5.38
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med (2011) 4.10
The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer? EMBO Rep (2010) 4.05
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell (2012) 3.39
Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res (2010) 3.24
KRAS and YAP1 converge to regulate EMT and tumor survival. Cell (2014) 3.06
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest (2012) 2.95
Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov (2014) 2.77
Targeting protein prenylation for cancer therapy. Nat Rev Cancer (2011) 2.60
Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer (2012) 2.59
Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell (2014) 2.50
Therapeutic strategies for targeting ras proteins. Genes Cancer (2011) 2.45
c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell (2011) 2.28
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest (2011) 2.20
Inhibition of Ras for cancer treatment: the search continues. Future Med Chem (2011) 2.14
TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol Cell (2011) 2.13
TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell (2012) 2.08
CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PLoS One (2016) 2.08
EMT is the dominant program in human colon cancer. BMC Med Genomics (2011) 2.05
Treating ALK-positive lung cancer--early successes and future challenges. Nat Rev Clin Oncol (2012) 1.97
Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One (2009) 1.94
Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov (2013) 1.93
Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst (2010) 1.92
The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins. Nat Cell Biol (2011) 1.87
The molecular pathology of cancer. Nat Rev Clin Oncol (2010) 1.86
The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest (2012) 1.86
Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A (2012) 1.82
Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir (2009) 1.79
Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation. J Biol Chem (2011) 1.74
Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther (2011) 1.74
Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer (2014) 1.71
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov (2015) 1.64
Roles for KRAS in pancreatic tumor development and progression. Gastroenterology (2013) 1.61
Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res (2013) 1.56
Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Res (2010) 1.52
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med (2011) 1.52
The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol (2017) 1.52
Molecular biology of lung cancer: clinical implications. Clin Chest Med (2011) 1.47
FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res (2014) 1.46
MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. Int J Oncol (2012) 1.46
Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell (2012) 1.44
Decoding and unlocking the BCL-2 dependency of cancer cells. Nat Rev Cancer (2013) 1.36
Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl (2013) 1.34
Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer Res (2010) 1.31
Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res (2011) 1.31
Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? Lung Cancer (2010) 1.30
A kinase shRNA screen links LATS2 and the pRB tumor suppressor. Genes Dev (2011) 1.30
Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS One (2012) 1.27
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med (2012) 1.27
MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS One (2012) 1.27
Control of alveolar differentiation by the lineage transcription factors GATA6 and HOPX inhibits lung adenocarcinoma metastasis. Cancer Cell (2013) 1.27
Expanding roles of ZEB factors in tumorigenesis and tumor progression. Am J Cancer Res (2011) 1.26
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov (2014) 1.26
Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci U S A (2013) 1.26
RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. Cancer Discov (2013) 1.25
ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest (2014) 1.22
KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. J Clin Invest (2013) 1.21
Kras as a key oncogene and therapeutic target in pancreatic cancer. Front Physiol (2014) 1.19
Vimentin is sufficient and required for wound repair and remodeling in alveolar epithelial cells. FASEB J (2011) 1.18
ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition. Cancer Res (2013) 1.17
An inducible kras(V12) transgenic zebrafish model for liver tumorigenesis and chemical drug screening. Dis Model Mech (2011) 1.17
MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. J Pathol (2013) 1.17
K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PLoS One (2012) 1.16
Outlier kinase expression by RNA sequencing as targets for precision therapy. Cancer Discov (2013) 1.13
PTTG1 oncogene promotes tumor malignancy via epithelial to mesenchymal transition and expansion of cancer stem cell population. J Biol Chem (2012) 1.13
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2016) 1.13
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene (2011) 1.12
KRAS as a Therapeutic Target. Clin Cancer Res (2015) 1.11
Getting Syk: spleen tyrosine kinase as a therapeutic target. Trends Pharmacol Sci (2014) 1.10
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize? Clin Cancer Res (2015) 1.08
Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets (2010) 1.07
TGF-β and αvβ6 integrin act in a common pathway to suppress pancreatic cancer progression. Cancer Res (2012) 1.06
The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells. Carcinogenesis (2011) 1.05
The genomics of lung adenocarcinoma: opportunities for targeted therapies. Genes Cancer (2010) 1.05
PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res (2013) 1.04
A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells. Cancer Biol Ther (2011) 1.03
The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinoma. Elife (2015) 1.03
Targeting the RAS oncogene. Expert Opin Ther Targets (2013) 1.02
FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells. Oncotarget (2015) 1.01
MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. Oncotarget (2014) 1.01
RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally. Front Genet (2012) 0.99
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin Cancer Res (2014) 0.99
Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential. J Exp Med (2014) 0.99
TPL2 kinase is a suppressor of lung carcinogenesis. Proc Natl Acad Sci U S A (2013) 0.99
Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling. PLoS One (2010) 0.98
Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med (2012) 0.96
Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations. Front Oncol (2012) 0.96
Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proc Natl Acad Sci U S A (2012) 0.96
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer Cell (2015) 0.96
The RalB small GTPase mediates formation of invadopodia through a GTPase-activating protein-independent function of the RalBP1/RLIP76 effector. Mol Cell Biol (2012) 0.95
Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov (2014) 0.95
Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes Dis (2015) 0.94
Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells. Cancer Metab (2014) 0.94
Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors. Cancer Res (2011) 0.94
SIGNATURE: a workbench for gene expression signature analysis. BMC Bioinformatics (2011) 0.94
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol (2003) 84.79
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89
Identifying biological themes within lists of genes with EASE. Genome Biol (2003) 31.72
Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A (2002) 30.32
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 28.95
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer (2007) 18.69
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84
Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science (2002) 14.20
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature (2001) 10.56
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev (2003) 8.27
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2006) 8.26
Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A (1987) 7.12
Amplification of endogenous myc-related DNA sequences in a human myeloid leukaemia cell line. Nature (1982) 6.11
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev (2006) 5.53
Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res (2005) 5.33
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet (2008) 5.07
Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res (2003) 4.30
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med (2007) 3.99
High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A (2004) 3.75
R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther (2006) 3.46
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
Allele-specific amplification in cancer revealed by SNP array analysis. PLoS Comput Biol (2005) 2.84
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res (2008) 2.71
Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci U S A (2008) 2.53
Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell (2007) 2.48
Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol (2005) 2.39
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol (2004) 2.32
Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res (2006) 2.12
Structure and function of Syk protein-tyrosine kinase. J Biochem (2001) 2.09
Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia (2004) 2.08
Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res (1990) 1.90
Ras family signaling: therapeutic targeting. Cancer Biol Ther (2003) 1.74
Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res (2005) 1.57
Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. Mol Cancer Res (2007) 1.49
Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res (1988) 1.45
Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett (2007) 1.43
Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth. Methods Enzymol (2006) 1.11
Src, chemoresistance and epithelial to mesenchymal transition: are they related? Anticancer Drugs (2007) 1.10
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev (2003) 8.27
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2006) 8.26
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77
Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell (2009) 7.39
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res (2008) 6.71
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 6.53
Pancreatic adenocarcinoma. N Engl J Med (2014) 6.21
Pancreatic cancers require autophagy for tumor growth. Genes Dev (2011) 6.17
Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev (2004) 5.00
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res (2012) 4.34
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab (2010) 4.08
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet (2005) 4.00
Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science (2011) 3.77
High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A (2004) 3.75
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov (2009) 3.64
The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature (2010) 3.55
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med (2012) 3.44
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell (2010) 3.40
RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature (2012) 3.40
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell (2012) 3.39
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer (2010) 3.33
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett (2009) 3.19
Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell (2005) 3.15
Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov (2013) 3.11
Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell (2013) 3.04
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A (2012) 2.66
YAP mediates crosstalk between the Hippo and PI(3)K–TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol (2012) 2.59
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood (2007) 2.51
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology (2014) 2.40
STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res (2011) 2.35
Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc Natl Acad Sci U S A (2002) 2.32
A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med (2008) 2.31
Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol (2009) 2.27
LKB1 (XEEK1) regulates Wnt signalling in vertebrate development. Nat Cell Biol (2003) 2.24
Somatic LKB1 mutations promote cervical cancer progression. PLoS One (2009) 2.21
Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology (2009) 2.17
PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov (2011) 2.14
Cancer: drivers and passengers. Nature (2007) 2.11
TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell (2012) 2.08
Amplification-free digital gene expression profiling from minute cell quantities. Nat Methods (2010) 2.07
Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med (2008) 2.06
Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. Mol Cell Biol (2008) 1.96
DOCK4, a GTPase activator, is disrupted during tumorigenesis. Cell (2003) 1.94
Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res (2010) 1.94
Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell (2011) 1.92
Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discov (2012) 1.86
Hippo signaling regulates differentiation and maintenance in the exocrine pancreas. Gastroenterology (2013) 1.85
Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res (2012) 1.83
Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate (2006) 1.78
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res (2006) 1.75
LKB1 regulates pancreatic beta cell size, polarity, and function. Cell Metab (2009) 1.70
Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res (2008) 1.67
Pancreatic adenocarcinoma. N Engl J Med (2014) 1.67
Rassf family of tumor suppressor polypeptides. J Biol Chem (2008) 1.63
Protein kinases of the Hippo pathway: regulation and substrates. Semin Cell Dev Biol (2012) 1.61
Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. Cancer Discov (2012) 1.56
Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet (2009) 1.55
Role of the SIK2-p35-PJA2 complex in pancreatic β-cell functional compensation. Nat Cell Biol (2014) 1.55
Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res (2009) 1.54
Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res (2010) 1.48
Loss of Lkb1 in adult beta cells increases beta cell mass and enhances glucose tolerance in mice. Cell Metab (2009) 1.47
Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res (2012) 1.47
LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis. Nat Genet (2008) 1.46
LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis. Cancer Res (2008) 1.42
Identification of novel alternative splice isoforms of circulating proteins in a mouse model of human pancreatic cancer. Cancer Res (2009) 1.40
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer (2011) 1.36
YAP oncogene overexpression supercharges colon cancer proliferation. Cell Cycle (2012) 1.34
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res (2014) 1.33
Mechanisms of acquired resistance to targeted cancer therapies. Future Oncol (2012) 1.33
p190 Rho-GTPase activating protein associates with plexins and it is required for semaphorin signalling. J Cell Sci (2005) 1.31
Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov (2013) 1.27
Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. Dis Model Mech (2010) 1.27
Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J Biol Chem (2013) 1.25
Targeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis. Mol Cell Biol (2006) 1.24
Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway. Biochem Biophys Res Commun (2009) 1.22
Hedgehog promotes neovascularization in pancreatic cancers by regulating Ang-1 and IGF-1 expression in bone-marrow derived pro-angiogenic cells. PLoS One (2010) 1.21
KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. J Clin Invest (2013) 1.21
Dose-dependent roles for canonical Wnt signalling in de novo crypt formation and cell cycle properties of the colonic epithelium. Development (2013) 1.19
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res (2010) 1.13
Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock". Biochem Pharmacol (2010) 1.13
Lysine-specific demethylase 2B (KDM2B)-let-7-enhancer of zester homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells. J Biol Chem (2011) 1.12
Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. Clin Cancer Res (2008) 1.12
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology (2015) 1.11
Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clin Cancer Res (2009) 1.10
Oncogenic K-ras "addiction" and synthetic lethality. Cell Cycle (2009) 1.08
Sin3B expression is required for cellular senescence and is up-regulated upon oncogenic stress. Cancer Res (2009) 1.07